Edwards Lifesciences Corporation (EW) Revenue by Segment
Edwards Lifesciences revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Edwards Lifesciences's largest business segment was United States, with $1.00 billion or 58% of revenue, up 12.8% from a year earlier. Next: Europe (25%), Rest of World (12%) and Japan (6%).
By product or service, Transcatheter Aortic Valve Replacement brought in 72%, Surgical brought in 16% and Transcatheter Mitral and Tricuspid Therapies brought in 11% of revenue in Q2 fiscal 2026.
By region, United States brought in 59%, Europe brought in 24% and Rest of World brought in 11% of revenue in Q3 fiscal 2024.
The fastest-growing business segment from a year earlier was Rest of World (+19.2%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Edwards Lifesciences Corporation
Revenue breakdown
Fiscal quarters, from company filings
Edwards Lifesciences revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $1.0B | $937.6M | $907.5M | $889.7M | 58% |
| Europe | $439.6M | $442.6M | $387.9M | $378.2M | 25% |
| Rest of World | $201.5M | $177.8M | $167.6M | $169.0M | 12% |
| Japan | $96.4M | $90.6M | $90.1M | $95.3M | 6% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Edwards Lifesciences revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.3B | $1.2B | $1.1B | $1.1B | 72% |
| Surgical | $284.1M | $276.2M | – | $266.8M | 16% |
| Transcatheter Mitral and Tricuspid Therapies | $198.6M | $175.1M | $145.2M | $134.5M | 11% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Edwards Lifesciences revenue by region, last 4 quarters
| Region | Q3 FY24 | Q3 FY23 | Q3 FY22 | Q2 FY22 | Share |
|---|---|---|---|---|---|
| United States | $804.6M | $735.9M | $786.8M | $800.8M | 59% |
| Europe | $319.8M | $286.5M | $270.1M | $302.8M | 24% |
| Rest of World | $148.6M | $135.2M | $158.0M | $147.4M | 11% |
| Japan | $81.4M | $85.8M | $104.1M | $122.9M | 6% |
In USD, fiscal quarters as reported; share = part of Q3 FY24 revenue.
Questions and answers
What are Edwards Lifesciences's business segments?
United States, Europe, Rest of World and Japan (as reported for Q2 fiscal 2026).
Which business segment makes the most money for Edwards Lifesciences?
United States: $1.00 billion, or 58% of revenue, in Q2 fiscal 2026.
What are Edwards Lifesciences's main products and services?
By revenue in Q2 fiscal 2026: Transcatheter Aortic Valve Replacement (72%), Surgical (16%) and Transcatheter Mitral and Tricuspid Therapies (11%).
Where does Edwards Lifesciences make its money?
By region in Q3 fiscal 2024: United States (59%), Europe (24%), Rest of World (11%) and Japan (6%).
